Glutamine
As of the edition of 20 October 2026, Glutamine is a small molecule: marketed, first approved in 1988 (CH).
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2004
- Kind
- Small molecule
- Brand name
- Nutrestore
- First approved
- 27 July 1988 (CH)
- Approvals on record
- 5 in 3 regions
- Holder of the most recent approval
- MYnd Analytics; 4 holders in all
- Registered trials
- 61, 17 stopped early
- Disease areas
- Blood and lymph; Cancer; Inherited and neonatal; Immune system; Digestive system; Infections
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 12 | 5 | 0 | 2 |
| Phase 1 | 10 | 6 | 0 | 3 |
| Phase 2 | 17 | 7 | 1 | 9 |
| Phase 3 | 17 | 13 | 0 | 2 |
| Phase 4 | 5 | 2 | 0 | 1 |
| All trials | 61 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| IBSA Institut Biochimique | Applicant | 1997 to now |
| MYnd Analytics | Acquired holder and Lead sponsor of trials | 2004 to now |